Personalized modeling for drug concentration prediction using Support Vector Machine

Building a personalized model to describe the drug concentration inside the human body for each patient is highly important to the clinical practice and demanding to the modeling tools. Instead of using traditional explicit methods, in this paper we propose a machine learning approach to describe the relation between the drug concentration and patients' features. Machine learning has been largely applied to analyze data in various domains, but it is still new to personalized medicine, especially dose individualization. We focus mainly on the prediction of the drug concentrations as well as the analysis of different features' influence. Models are built based on Support Vector Machine and the prediction results are compared with the traditional analytical models.

Convention de Londres du 21 mai 1833, suivie de la convention conclue, à Mayence, le 31 mars 1831, relativement à la navigation du Rhin

[Traité. 1833-05-21. Londres (français)]

Your Personalized Medicare Manager Is Waiting for You Online, 2007

Go to MyMedicare.gov and get the personalized information you need to make better health care choices. With this exciting new web tool, you can make the best health care decisions for your personal needs. MyMedicare.gov puts you in control.

L'art de naviguer : contenant toutes les reigles, secrets, & enseignemens necessaires à la bonne navigation ([Reprod.]) / de M. Pierre de Medina ; traduict de Castillan en François, avec augmentation & illustration de plusieurs figures et annotations par Nicolas de Nicolai,...

Collection : French books before 1601 ; 69.4

Recueil d'appareils à vapeur employés aux travaux de navigation et de chemins de fer / par A. Castor,... ; par M. Baude,...

Comprend : Rapport sur les travaux de fondation du pont du Rhin ...

Carte Phisique [sic] Administrative et Routière de la France donnant la Belgique et une partie de la Hollande : Indiquant les Relais de Poste, les Eaux Thermales et la Navigation Intérieure / par A. Beaupré

Échelle(s) : [ca 1:1 754 000], 10 Myriamètres [ = 5,7 cm]

Carte générale des Îles Britanniques contenant l'Angleterre, l'Écosse et l'Irlande : indiquant les principales routes, les canaux de navigation, les chemins de fer exécutés et en cours d'exécution dans la Grande-Bretagne / par J. Andriveau ; le burin par Piat ; écrit par Arnoul

Échelle(s) : [ca 1:1 4640 000], échelle de 25 lieues communes de France [= 7,6 cm]

Spaced training facilitates long-term retention of place navigation in adult but not in adolescent rats

Young and adult Long Evans rats were tested in the water maze according to two different procedures: half of the subjects were given one session of four trials a day for 6 days, whereas the other subjects had the same amount of training massed in 1 day. For both conditions, a 14-day retention interval was then introduced to test long-term memory. This was followed by a four-trial reversal session. All groups showed a significant learning curve, but escape latencies were shorter for the adult than for the young rats, without differential effect of the training procedure. A first probe trial (PT1) confirmed similar accurate short-term retention in all the groups. But unimpaired long-term memory was only seen in the adult rats trained with the spaced procedure. The young rats trained over 1 day also showed some retention of the platform location after 14 days, but not the other two groups. Reversal acquisition of the new platform location was rapid in the four groups. These results indicate that although accurate short-term spatial memory in the water maze is seen after a 1-day massed training in both age groups, unimpaired long-term retention is only observed in adult rats trained with 24-h inter-session intervals.

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

The DNA repair enzyme O(6)-methylguanine-DNA methyltransferase (MGMT) antagonizes the genotoxic effects of alkylating agents. MGMT promoter methylation is the key mechanism of MGMT gene silencing and predicts a favorable outcome in patients with glioblastoma who are exposed to alkylating agent chemotherapy. This biomarker is on the verge of entering clinical decision-making and is currently used to stratify or even select glioblastoma patients for clinical trials. In other subtypes of glioma, such as anaplastic gliomas, the relevance of MGMT promoter methylation might extend beyond the prediction of chemosensitivity, and could reflect a distinct molecular profile. Here, we review the most commonly used assays for evaluation of MGMT status, outline the prerequisites for standardized tests, and evaluate reasons for difficulties in reproducibility. We critically discuss the prognostic and predictive value of MGMT silencing, reviewing trials in which patients with different types of glioma were treated with various chemotherapy schedules, either up-front or at recurrence. Standardization of MGMT testing requires comparison of different technologies across laboratories and prospectively validated cut-off values for prognostic or predictive effects. Moreover, future clinical trials will need to determine, for each subtype of glioma, the degree to which MGMT promoter methylation is predictive or prognostic, and whether testing should become routine clinical practice.